Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis.
Multiple sclerosis: Spinal cord grey matter loss correlates with disability in MS.
Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
Materials for stem cell factories of the future.
Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating Batf.
Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis.
B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.
Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis.
A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01.
Early activation of CD4+ and CD8+ T lymphocytes by myelin basic protein in subjects with MS.
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.
Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.
Mapi Pharma granted United States patent covering glatiramer depot for multiple sclerosis
[Optical coherence tomography in multiple sclerosis].
MRI in multiple sclerosis: a review of the current literature.
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis
Distinct profiles of myelin distribution along single axons of pyramidal neurons in the neocortex.
Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly.
Bridging the Brain Disease Knowledge Gap Through Computational Modeling and Systems Biology
Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus.
Potential T cell epitopes of Mycobacterium tuberculosis that can instigate molecular mimicry against host: implications in autoimmune pathogenesis.
Vinpocetine inhibits oligodendroglial precursor cell differentiation.
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Concurrent saturation transfer contrast in in vivo brain by a uniform magnetization transfer MRI.
Pages
« first
‹ previous
…
153
154
155
156
157
158
159
160
161
…
next ›
last »